在美国 FDA 批准其马来西亚胰岛素设施后，Biocon 的股价上涨，提振了生物仿制药的前景。 Biocon's stock rises after US FDA clears its Malaysia insulin facility, boosting biosimilar prospects.

美国FDA清理了马来西亚胰岛素设施,将其归类为“自愿行动指示”(VAI)之后,Biocon Ltd的股份猛增了5%。 Biocon Ltd's stock jumped 5% after the USFDA cleared its Malaysia insulin facility, classifying it as "Voluntary Action Indicated" (VAI). 这种清关经过以往的管制障碍之后,使公司能够将设施的产品存档。 This clearance, following a previous regulatory hurdle, allows the company to file products from the facility. 分析家预测,对Biocon的生物相似发射管道的信心将提高,预计2025年的年收入将增长12亿美元。 Analysts predict increased confidence in Biocon's biosimilar launch pipeline, with expected annual revenue growth to $1.2 billion in 2025. 最近美国FDA的批准和即将推出的产品是公司增长的关键因素。 Recent USFDA approvals and upcoming product launches are key factors for the company's growth.